Summit Therapeutics Shares (SMMT) Drop Overnight As New Bear Emerges

Summit Therapeutics shares (NASDAQ: SMMT) dropped 5.5% in overnight trading after Bernstein initiated coverage with a stark warning that the clinical-stage biotech’s entire late-stage pipeline faces significant risk of failure.

The SMMT stock price fell 5.5% to $16.51 in after-hours trading following the coverage, extending a 2.35% loss from the close that has added to Summit Therapeutics’ 28.93% decline over the last month of trading . Bernstein analyst Jeffrey Walch assigned an Underperform rating with a $7.70 price target, implying more than 50% downside from current levels, in a bearish note.

Behind The Call

The bearish call centres on Bernstein’s expectation that all three of Summit’s ongoing Phase 3 trials will fail to achieve statistically significant results on their primary endpoints. Walch stated that the firm believes the long-term outlook for the company is “not on solid footing,” highlighting that Summit has no approved drugs, no revenue, and no additional late-stage assets beyond its ivonescimab programme.

Ivonescimab, a PD-1 × VEGF bispecific antibody, represents Summit’s entire commercial bet. The company is running three Phase 3 trials under the HARMONi umbrella, positioning the drug as a potential competitor to Merck’s blockbuster Keytruda in various non-small cell lung cancer settings. The trials include HARMONi (EGFR-mutant NSCLC post-EGFR-TKI), HARMONi-2 (first-line monotherapy versus pembrolizumab), and HARMONi-3 (first-line combination therapy versus Keytruda plus chemotherapy).

Summit has reported positive Phase 3 data from the initial HARMONi trial, demonstrating statistically significant progression-free survival improvement with a hazard ratio of approximately 0.52. However, overall survival, a critical endpoint for FDA approval, did not reach statistical significance in the initial readout, with a hazard ratio of 0.79 showing a trend but not definitive benefit. This gap is central to the regulatory risk that Bernstein has flagged, particularly given that the FDA has previously signalled the need for statistically significant overall survival data for approval in this indication.

The company has undergone notable protocol amendments in its HARMONi-3 trial, including design and endpoint changes, which coincided with earlier stock selloffs and raised questions about whether original assumptions regarding effect size or patient populations were holding up. These modifications have added to execution risk concerns among more cautious market participants.

Despite the bearish initiation, Summit maintains a clear regulatory pathway. The company has communicated its intention to file a Biologics License Application in the United States for ivonescimab plus chemotherapy in EGFR-mutant NSCLC, targeting a submission around late 2025. Management is leveraging both its own trial data and global Phase 3 results generated by partner Akeso as part of a totality-of-evidence approach.

The Other Side

Bulls point to additional positive data from related trials, including an overall survival-positive Phase 3 result in HARMONi-A in another NSCLC segment, which they argue demonstrates that ivonescimab is not an unproven molecule but has shown clinically meaningful effects across multiple settings. The breadth of the global programme spanning combination therapy, monotherapy, and multiple NSCLC populations, suggests a potentially large addressable market if approvals are secured.

As a clinical-stage company with no commercial revenue, Summit is entirely dependent on equity financing to fund operations through pivotal data readouts and regulatory submissions. The company has executed well-timed capital raises in the past, including one that coincided with a short squeeze that drove shares from around $17 to $28. However, any sign of trial weakness or regulatory friction could rapidly translate into dilutive capital raises, compounding downside risk.

The Bernstein call represents a high-profile, fundamentally argued sell-equivalent view in a name where sentiment had been largely shaped by bullish interpretations of the Keytruda-challenger narrative. The explicit recommendation to short positions frames the call as a catalyst for negative sentiment shifts and potential repositioning among generalist and risk-averse funds. Near term, the signalling effect of a fresh Underperform rating at a major research house tends to bring incremental selling, hedging by long holders, and possibly new short interest.